Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.45 |
| ▸ | PDE4A | P27815 | 7/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165893 | 0.88 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL5515932 | 0.88 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL3528755 | 0.88 | PDE4B (0.43) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL1826949 | 0.88 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL13002994 | 0.88 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL5511996 | 0.88 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL1382915 | 0.87 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL13165895 | 0.87 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL5509175 | 0.87 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DTP53 | |
| SCHEMBL1823618 | 0.87 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | MCL1, APC, THPO | PDE4B 729/4885PDE4C 403/4885PDE4A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.